Skip to content

Reported March 18, 2025 · Before market open

Next report

Aug 6, 2026 (in a month)
EPS estimate-$0.30

Financials

Q4 2024

Income statement

See full
Revenue$7.2M+14.4%
Gross profit$6.4M+19.4%
Operating income-$18.9M-7.0%
Net income-$18.3M-12.3%
EPS (diluted)-$0.68-13.3%

Balance sheet

See full
Cash & equivalents$28.7M-54.4%
Total debt$833.0K-34.3%
Total equity$52.5M-50.1%
Total assets$70.3M-46.9%

Cash flow

See full
Operating cash flow-$15.1M-56.1%
CapEx$186.0K-77.2%
Free cash flow-$15.2M-45.7%

Valuation & ratios

Profitability

See full
Gross margin88.4%-0.1pp
Operating margin-259.6%-28.0pp
Net margin-245.1%-20.7pp
FCF margin-235.6%-21.1pp

Returns & leverage

See full
Return on equity-80.8%+131pp
Debt / equity0.0×
Current ratio3.6×-1.1×

Versus estimates

Ask the moment Whitehawk Therapeutics, Inc. Common Stock reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Whitehawk Therapeutics, Inc. Common Stock report Q4 2024 earnings?
Whitehawk Therapeutics, Inc. Common Stock (WHWK) reported Q4 2024 earnings on March 18, 2025 before market open.
What were Whitehawk Therapeutics, Inc. Common Stock's Q4 2024 revenue and EPS?
Whitehawk Therapeutics, Inc. Common Stock reported revenue of $7.2M and diluted EPS of $-0.67 for Q4 2024.
Did Whitehawk Therapeutics, Inc. Common Stock beat estimates in Q4 2024?
EPS missed the consensus estimate of $-0.22 by $0.45.
Where can I find Whitehawk Therapeutics, Inc. Common Stock's Q4 2024 SEC filings?
You can read the 10-K periodic report (0001628280-25-015269) directly on SEC EDGAR. The filing index links above go to sec.gov.